Amazon Ad

Advertisement

test

Covaxin phase 3 data shows 77.8% efficacy: Lancet

A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.

from Times of India https://ift.tt/30aDSMa
Covaxin phase 3 data shows 77.8% efficacy: Lancet Covaxin phase 3 data shows 77.8% efficacy: Lancet Reviewed by GYM LOVER KATTA�� on 15:05 Rating: 5

No comments:

Powered by Blogger.